Alemtuzumab
- Generic Name
- Alemtuzumab
- Brand Names
- Campath, Lemtrada, MabCampath
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216503-57-0
- Unique Ingredient Identifier
- 3A189DH42V
- Background
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regio...
- Indication
用于烷化剂氟达拉滨（fludarabine）治疗失败的B细胞性慢性淋巴细胞白血病患者；亦可用于复发缓解型多发性硬化症治疗。
- Associated Conditions
- B-Cell Chronic Lymphocytic Leukemia, Kidney Transplant Rejection, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Steroid Refractory Acute Graft Versus Host Disease, T-cell Prolymphocytic Leukemia (T-PLL), Refractory Autoimmune Hemolytic Anemia, Refractory Idiopathic thrombocytopenic purpura
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Tolerance by Engaging Antigen During Cellular Homeostasis
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2024-01-26
- Target Recruit Count
- 8
- Registration Number
- NCT03504241
- Locations
- 🇺🇸
Duke University Health System, Durham, North Carolina, United States
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Paul Szabolcs
- Target Recruit Count
- 8
- Registration Number
- NCT03500731
- Locations
- 🇺🇸
UPMC Presbyterian, Pittsburgh, Pennsylvania, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)
- Conditions
- Interventions
- First Posted Date
- 2018-03-26
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Haukeland University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03477500
- Locations
- 🇳🇱
VUmc, Amsterdam, Netherlands
🇳🇴St. Olav's University Hospital, Trondheim, Norway
🇩🇰Rigshospitalet, Copenhagen, Denmark
Stem Cell Transplant in Patients With Severe Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Kathleen Dorritie
- Target Recruit Count
- 1
- Registration Number
- NCT03421756
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Precision Dosing of Alemtuzumab
- Conditions
- Interventions
- First Posted Date
- 2017-10-05
- Last Posted Date
- 2019-10-04
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 12
- Registration Number
- NCT03302754
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Neurofilaments for NEDA Assessing in MS
- Conditions
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 21
- Registration Number
- NCT03250169
- Locations
- 🇬🇧
Queen Mary University of London, London, England, United Kingdom
Nonmyeloablative Stem Cell Transplant in Children with Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 12
- Registration Number
- NCT03214354
- Locations
- 🇨🇦
Alberta Children's Hospital, Calgary, Alberta, Canada
The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis Patients
- Conditions
- Interventions
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Glostrup University Hospital, Copenhagen
- Target Recruit Count
- 35
- Registration Number
- NCT03193086
- Locations
- 🇩🇰
Functional Imaging Unit, Department of Clinical Physiology, Nuclear medicine and PET, Glostrup Hospital, Glostrup, Copenhagen Capital Region, Denmark
Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)
- Conditions
- Interventions
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 22
- Registration Number
- NCT03182426
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 9
- Registration Number
- NCT03135249
- Locations
- 🇺🇸
UT Southwestern Medical center, Dallas, Texas, United States
🇺🇸VA North Texas Health Care System, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.